CCS
FBT icon

Crosspoint Capital Strategies’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

Crosspoint Capital Strategies’s Portfolio FBT Stock Details FBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-6,170
Closed -$629K – 341
2015
Q4 		$629K Buy
+6,170
New +$664K 0.17% 133

Other funds holding FBT

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Crosspoint Capital Strategies's FBT Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of First Trust NYSE Arca Biotechnology Index Fund (FBT) in Q1 2016, closing a stake of 6,170 shares — an estimated $629K sold.

Crosspoint Capital Strategies first reported a position in FBT in Q4 2015 and held it in 1 quarter. The position peaked at $629K in Q4 2015. 107 funds tracked by Wall St. Rank hold FBT as of Q1 2016.

  • Crosspoint Capital Strategies reported no remaining First Trust NYSE Arca Biotechnology Index Fund position as of Q1 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 6,170 First Trust NYSE Arca Biotechnology Index Fund shares in Q1 2016, an estimated $629K.
  • Crosspoint Capital Strategies first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q4 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's First Trust NYSE Arca Biotechnology Index Fund position peaked at $629K in Q4 2015.
  • 107 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.